MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.amjcard.2024.07.002

Медицинская библиотека · The American journal of cardiology · 2024

Post-procedural Anticoagulation With Unfractionated Heparin in Acute Coronary Syndrome: Insight from the STOPDAPT-3 Trial.

Watanabe Hirotoshi, Natsuaki Masahiro, Morimoto Takeshi, Yamamoto Ko, Obayashi Yuki, Nishikawa Ryusuke, Hamatani Yasuhiro, Ando Kenji, Domei Takenori, Suwa Satoru, Ogita Manabu, Isawa Tsuyoshi, Takenaka Hiroyuki, Yamamoto Takashi, Ishikawa Tetsuya, Hisauchi Itaru, Wakabayashi Kohei, Onishi Yuko, Hibi Kiyoshi, Kawai Kazuya, Yoshida Ruka, Suzuki Hiroshi, Nakazawa Gaku, Kusuyama Takanori, Morishima Itsuro, Ono Koh, Kimura Takeshi, STOPDAPT-3 Investigators

Клиническое исследование IV фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

The current guidelines for acute coronary syndrome (ACS) discourage the use of anticoagulation after percutaneous coronary intervention (PCI) without specific indications, although the recommendation is not well supported by evidence. In this post hoc analysis of the ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 (STOPDAPT-3) trial, 30-day outcomes were compared between the 2 groups with and without post-PCI heparin administration among patients with ACS who did not receive mechanical support devices. The co-primary end points were the bleeding end point, defined as the Bleeding Academic Research Consortium type 3 or 5 bleeding, and the cardiovascular end point, defined as a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or ischemic stroke. Among 4,088 patients with ACS, 2,339 patients (57.2%) received post-PCI heparin. The proportion of patients receiving post-PCI heparin was higher among those with ST-elevation myocardial infarction compared with others (72.3% and 38.8%, p <0.001), and among patients with intraprocedural adverse angiographic findings compared with those without (67.6% and 47.5%, p <0.001). Post-PCI heparin compared with no post-PCI heparin was associated with a significantly increased risk of the bleeding end point (4.75% and 2.52%, adjusted hazard ratio 1.69, 95% confidence interval 1.15 to 2.46, p = 0.007) and a numerically increased risk of the cardiovascular end point (3.16% and 1.72%, adjusted hazard ratio 1.56, 95% confidence interval 0.98 to 2.46, p = 0.06). Higher hourly dose or total doses of heparin were also associated with higher incidence of both bleeding and cardiovascular events within 30 days. In conclusion, post-PCI anticoagulation with unfractionated heparin was frequently implemented in patients with ACS. Post-PCI heparin use was associated with harm in terms of increased bleeding without the benefit of reducing cardiovascular events. Trial identifier: STOPDAPT-3 ClinicalTrials.gov number, NCT04609111.

Для цитирования: Watanabe Hirotoshi, Natsuaki Masahiro, Morimoto Takeshi, Yamamoto Ko, Obayashi Yuki, Nishikawa Ryusuke, Hamatani Yasuhiro, Ando Kenji, Domei Takenori, Suwa Satoru, Ogita Manabu, Isawa Tsuyoshi, Takenaka Hiroyuki, Yamamoto Takashi, Ishikawa Tetsuya, Hisauchi Itaru, Wakabayashi Kohei, Onishi Yuko, Hibi Kiyoshi, Kawai Kazuya, Yoshida Ruka, Suzuki Hiroshi, Nakazawa Gaku, Kusuyama Takanori, Morishima Itsuro, Ono Koh, Kimura Takeshi, STOPDAPT-3 Investigators. Post-procedural Anticoagulation With Unfractionated Heparin in Acute Coronary Syndrome: Insight from the STOPDAPT-3 Trial.. The American journal of cardiology. 2024. DOI: 10.1016/j.amjcard.2024.07.002.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.